Kardigan, Inc. Common Stock (KARD) Stock
Fundamentals
Recent news

Kardigan to Present at Two September Investor Conferences
Kardigan to Present at Two September Investor Conferences
KARD

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
KARD

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
KARD

Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan rises in Nasdaq debut after upsized $400 million IPO
KARD
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 7 articles
published over the past 14 days
Latest news

Kardigan to Present at Two September Investor Conferences
Kardigan to Present at Two September Investor Conferences
KARD

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
KARD

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
KARD

Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan rises in Nasdaq debut after upsized $400 million IPO
KARD

Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan Announces Pricing of Upsized Initial Public Offering
KARD

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
KARD

Cardiovascular drug developer Kardigan files for US IPO
Cardiovascular drug developer Kardigan files for US IPO
KARD
About Kardigan, Inc. Common Stock
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. The company leverages deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. Its management team includes leaders from MyoKardia, Inc. ("MyoKardia") with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA | Co-Founder, President, CEO & Chairman | 1973 |
| Dr. Jay Edelberg M.D., Ph.D. | Co-founder & Chief Medical Officer | 1964 |
| Ms. Brianne Puglisi | Chief Financial Officer | 1987 |
| Dr. Bob McDowell Ph.D. | Co-founder & Scientific Advisor | — |
| Dr. Leslie A. Leinwand Ph.D. | Co-Founder | — |
| Dr. Elizabeth McNally M.D., Ph.D. | Co-Founder | 1961 |
| Mr. Donald Mackenzie Ph.D. | Chief Technical Operations Officer | — |
| Mr. Clayton Robertson | Vice President of Investor Relations | — |
| Mr. John B. Moriarty Jr., ESQ., J.D. | Chief Legal Officer & Corporate Secretary | 1968 |
| Ms. Emily Faucette | Chief Communications Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
4 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.4 | -13.6 | +1.0 | -24.5 |



